Retatrutide
10–60mg
Retatrutide 10mg 20mg 30mg 60mg
Research Compound Lyophilized Powder
Metabolic Science

Retatrutide

Triple-Receptor Metabolic Agonist

$69.00
Third-Party Lab Tested
COA With Every Order
Fast U.S. Shipping
Text Email

What It Is

A triple-receptor agonist that activates GLP-1, GIP, and glucagon receptors simultaneously. Retatrutide is currently in Phase 3 clinical trials.

How It Works

1
Retatrutide binds to three receptors simultaneously
→
2
GLP-1 and GIP pathways reduce appetite signaling
→
3
Glucagon receptor activation increases energy expenditure
→
4
Combined effect on metabolic rate and fat oxidation

What Researchers Study It For

Body weight and composition models
Glycemic control and insulin sensitivity
Energy expenditure and metabolic rate
Multi-receptor agonism mechanisms

Common Research Protocols

Retatrutide is currently under clinical investigation as a subcutaneous injection. Research protocols are defined within the context of ongoing clinical trials.

Community Interest Areas

The research community has shown intense interest in Retatrutide due to its triple-agonist mechanism, which distinguishes it from dual-agonist compounds like tirzepatide. Its ability to engage the glucagon receptor in addition to GLP-1 and GIP pathways has generated particular attention in metabolic research circles focused on energy expenditure.

Triple Agonist Simultaneously activates GLP-1, GIP, and glucagon receptors
Phase 3 Currently under clinical trial investigation (NCT05931367)

For research purposes only. Not intended for consumption, clinical application, or diagnostic use.

Research Fundamentals

What Are Peptides?

How peptides work at the cellular level — receptor binding, tissue repair, immune modulation, and metabolic function.

Read Article → Safety & Compliance

Are Peptides Safe?

An honest look at peptide safety — what research shows, the 2026 FDA reclassification, source quality, and key considerations.

Read Article →
Learn About Peptides